Monopar Q3 net loss improves to $2.0M; MNPR-101 radiopharma on track for first-in-human Dec 2023

Monopar Therapeutics

Net loss $2.0M ($0.14/share) vs $2.4M ($0.19) YoY; cash and equivalents $8.5M.
MNPR-101 radiopharma program to enter first-in-human study possibly as early as December 2023.
Camsirubicin Phase 1b at fifth dose cohort (650 mg/m^2); two patients showed tumor reductions of ~18% and 20%.
CTOS data: 9 of 14 stable disease, no DLT; one patient with LVEF decrease being assessed for cardiotoxicity.
Cash runway through November 2024; company expects to seek additional capital within 12 months.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monopar Therapeutics reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share, EPS $0.14 per share.

Period: third quarter ended September 30, 2023
Net income: Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share
EPS: $0.14 per share
Result: reported results

Exact text from the filing

Monopar Therapeutics Inc. issued a press release announcing its financial results and summarized recent developments for the third quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-23-031065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.